6533b82dfe1ef96bd1291bb8

RESEARCH PRODUCT

Acetylcholine receptors (muscarinic) in GtoPdb v.2021.3

Neil M. NathansonJürgen WessRudolf HammerR. A. John ChallissRichard M. EglenFred MitchelsonDavid BrownSophie J. BradleyCeline ValantHeinz KilbingerChris LangmeadFrederick J. EhlertAndrew B. TobinNoel J. BuckleyErnst MutschlerGünter LambrechtArthur ChristopoulosDavid M. ThalRoy D. SchwarzNigel J. M. BirdsallChristian C. Felder

subject

BradycardiaAtropinePilocarpineChemistryMuscarinic acetylcholine receptormedicinePharmacologymedicine.symptomMuscarinic AgentsEndogenous agonistAcetylcholinemedicine.drugAcetylcholine receptor

description

Muscarinic acetylcholine receptors (mAChRs) (nomenclature as agreed by the NC-IUPHAR Subcommittee on Muscarinic Acetylcholine Receptors [50]) are activated by the endogenous agonist acetylcholine. All five (M1-M5) mAChRs are ubiquitously expressed in the human body and are therefore attractive targets for many disorders. Functionally, M1, M3, and M5 mAChRs preferentially couple to Gq/11 proteins, whilst M2 and M4 mAChRs predominantly couple to Gi/o proteins. Both agonists and antagonists of mAChRs are clinically approved drugs, including pilocarpine for the treatment of elevated intra-ocular pressure and glaucoma, and atropine for the treatment of bradycardia and poisoning by muscarinic agents such as organophosphates.

yearjournalcountryeditionlanguage
2021-09-02IUPHAR/BPS Guide to Pharmacology CITE
https://doi.org/10.2218/gtopdb/f2/2021.3